Multiscale Modeling in Drug Discovery and Development: Future Opportunities and Present Challenges

Modeling and simulation (M&S) is a diverse discipline that uses tools from mathematics, statistics, and computer science to arrive at quantitative predictions. Its application to biological systems has a checkered history with respect to success and failure. The instances of failure may reflect the heterogeneity of M&S approaches. In order to ensure a successful outcome, M&S must be fit for purpose and responsive; connecting with biological concepts is critical; sharing of results has to be done properly; buy‐in is achieved in stages. These concepts are being applied in drug discovery and development and are yielding success. However, bottlenecks remain.

[1]  Marc R Gastonguay,et al.  Pharmacometrics: A Multidisciplinary Field to Facilitate Critical Thinking in Drug Development and Translational Research Settings , 2008, Journal of clinical pharmacology.

[2]  Jon Wakefield,et al.  Population modelling in drug development , 1999, Statistical methods in medical research.

[3]  D. Lauffenburger,et al.  Applying computational modeling to drug discovery and development. , 2006, Drug discovery today.

[4]  C T Dollery.  The Challenge of Complexity , 2010, Clinical pharmacology and therapeutics.

[5]  D. Noble.  Claude Bernard, the first systems biologist, and the future of physiology , 2008, Experimental physiology.

[6]  Denis Noble,et al.  The Cardiac Physiome: perspectives for the future , 2009, Experimental physiology.

[7]  P. Sorger.  A reductionist's systems biology: opinion. , 2005, Current opinion in cell biology.

[8]  R MAIRE,et al.  [Perspectives of the future]. , 1950, Le Medecin generaliste de France.

[9]  Ivan Nestorov,et al.  Whole Body Pharmacokinetic Models , 2003, Clinical pharmacokinetics.

[10]  D. Noble.  Systems biology and the heart. , 2006, Bio Systems.

[11]  Narayanan Surendran,et al.  Implementation of an ADME enabling selection and visualization tool for drug discovery. , 2004, Journal of pharmaceutical sciences.

[12]  Denis Noble,et al.  The IUPS human physiome project , 2002, Pflügers Archiv.

[13]  P. Vicini,et al.  Model-based approaches to biomarker discovery and evaluation: a multidisciplinary integrated review. , 2002, Critical reviews in biomedical engineering.

[14]  V. Quaranta,et al.  Integrative mathematical oncology , 2008, Nature Reviews Cancer.

[15]  Franco Lombardo,et al.  Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug Compounds , 2008, Drug Metabolism and Disposition.

[16]  Vikram Sinha,et al.  Pharmacokinetics/pharmacodynamics and the stages of drug development: Role of modeling and simulation , 2005, The AAPS Journal.

[17]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[18]  Paul F. Reynolds,et al.  The Role of Modeling and Simulation , 2008 .

[19]  Rakesh K Jain.  Taming vessels to treat cancer. , 2008, Scientific American.

[20]  Johan Gabrielsson,et al.  Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. , 2009, Future medicinal chemistry.

[21]  D. Noble,et al.  Systems biology and the virtual physiological human , 2009, Molecular systems biology.

[22]  M. Peitsch,et al.  The application of systems biology to drug discovery. , 2006, Current opinion in chemical biology.

[23]  Sanjiv Sam Gambhir,et al.  Molecualr imaging of cancer: from molecules to humans. Introduction. , 2008, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  J. Mandema,et al.  Use of Modeling and Simulation to Optimize Dose-Finding Strategies , 2002 .

[25]  Viswanath Devanarayan,et al.  Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement , 2006, Pharmaceutical Research.

[26]  Steven W. Martin,et al.  The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. , 2007, Drug discovery today.

[27]  N H Holford,et al.  Drug treatment effects on disease progression. , 2001, Annual review of pharmacology and toxicology.

[28]  DE Mager,et al.  Development of Translational Pharmacokinetic–Pharmacodynamic Models , 2008, Clinical pharmacology and therapeutics.

[29]  Janet Woodcock,et al.  The FDA critical path initiative and its influence on new drug development. , 2008, Annual review of medicine.

[30]  Y. Lazebnik.  Can a biologist fix a radio? — or, what I learned while studying apoptosis , 2004, Biochemistry (Moscow).